vs
LivaNova PLC（LIVN）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
LivaNova PLC的季度营收约是Rapid7, Inc.的1.7倍（$360.9M vs $217.4M），LivaNova PLC净利率更高（8.6% vs 1.4%，领先7.1%），LivaNova PLC同比增速更快（12.1% vs 0.5%），LivaNova PLC自由现金流更多（$50.2M vs $36.4M），过去两年LivaNova PLC的营收复合增速更高（10.6% vs 3.0%）
LivaNova PLC是一家深耕医疗设备领域的企业，总部位于英国，核心业务为研发心脏外科及神经调控类医疗设备。该公司由美国Cyberonics公司与意大利Sorin公司于2015年以27亿美元对价合并成立，目前在纳斯达克挂牌交易，股票代码为LIVN。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
LIVN vs RPD — 直观对比
营收规模更大
LIVN
是对方的1.7倍
$217.4M
营收增速更快
LIVN
高出11.6%
0.5%
净利率更高
LIVN
高出7.1%
1.4%
自由现金流更多
LIVN
多$13.7M
$36.4M
两年增速更快
LIVN
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $360.9M | $217.4M |
| 净利润 | $30.9M | $3.1M |
| 毛利率 | 65.2% | 68.9% |
| 营业利润率 | 11.8% | 1.0% |
| 净利率 | 8.6% | 1.4% |
| 营收同比 | 12.1% | 0.5% |
| 净利润同比 | -44.7% | 44.1% |
| 每股收益（稀释后） | $0.57 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LIVNRPD
| Q4 25 | $360.9M | $217.4M | ||
| Q3 25 | $357.8M | $218.0M | ||
| Q2 25 | $352.5M | $214.2M | ||
| Q1 25 | $316.9M | $210.3M | ||
| Q4 24 | $321.8M | $216.3M | ||
| Q3 24 | $318.1M | $214.7M | ||
| Q2 24 | $318.6M | $208.0M | ||
| Q1 24 | $294.9M | $205.1M |
净利润LIVNRPD
| Q4 25 | $30.9M | $3.1M | ||
| Q3 25 | $26.8M | $9.8M | ||
| Q2 25 | $27.2M | $8.3M | ||
| Q1 25 | $-327.3M | $2.1M | ||
| Q4 24 | $55.9M | $2.2M | ||
| Q3 24 | $33.0M | $15.4M | ||
| Q2 24 | $16.3M | $6.5M | ||
| Q1 24 | $-41.9M | $1.4M |
毛利率LIVNRPD
| Q4 25 | 65.2% | 68.9% | ||
| Q3 25 | 68.4% | 70.2% | ||
| Q2 25 | 67.8% | 70.6% | ||
| Q1 25 | 69.7% | 71.7% | ||
| Q4 24 | 68.2% | 69.5% | ||
| Q3 24 | 70.8% | 70.6% | ||
| Q2 24 | 68.7% | 70.7% | ||
| Q1 24 | 70.3% | 70.3% |
营业利润率LIVNRPD
| Q4 25 | 11.8% | 1.0% | ||
| Q3 25 | 15.1% | 2.7% | ||
| Q2 25 | 15.4% | 1.6% | ||
| Q1 25 | 15.3% | -0.0% | ||
| Q4 24 | 11.5% | 3.4% | ||
| Q3 24 | 11.2% | 6.0% | ||
| Q2 24 | 12.6% | 2.5% | ||
| Q1 24 | 5.5% | 4.7% |
净利率LIVNRPD
| Q4 25 | 8.6% | 1.4% | ||
| Q3 25 | 7.5% | 4.5% | ||
| Q2 25 | 7.7% | 3.9% | ||
| Q1 25 | -103.3% | 1.0% | ||
| Q4 24 | 17.4% | 1.0% | ||
| Q3 24 | 10.4% | 7.2% | ||
| Q2 24 | 5.1% | 3.1% | ||
| Q1 24 | -14.2% | 0.7% |
每股收益（稀释后）LIVNRPD
| Q4 25 | $0.57 | $0.05 | ||
| Q3 25 | $0.49 | $0.15 | ||
| Q2 25 | $0.50 | $0.13 | ||
| Q1 25 | $-6.01 | $0.03 | ||
| Q4 24 | $1.04 | $0.08 | ||
| Q3 24 | $0.60 | $0.21 | ||
| Q2 24 | $0.30 | $0.09 | ||
| Q1 24 | $-0.78 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $635.6M | $474.7M |
| 总债务越低越好 | $376.1M | — |
| 股东权益账面价值 | $1.2B | $154.7M |
| 总资产 | $2.6B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.31× | — |
8季度趋势，按日历期对齐
现金及短期投资LIVNRPD
| Q4 25 | $635.6M | $474.7M | ||
| Q3 25 | $646.1M | $407.1M | ||
| Q2 25 | $593.6M | $511.7M | ||
| Q1 25 | $738.4M | $493.5M | ||
| Q4 24 | $428.9M | $521.7M | ||
| Q3 24 | $346.4M | $443.7M | ||
| Q2 24 | $329.2M | $442.6M | ||
| Q1 24 | $309.2M | $411.7M |
总债务LIVNRPD
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
股东权益LIVNRPD
| Q4 25 | $1.2B | $154.7M | ||
| Q3 25 | $1.2B | $127.2M | ||
| Q2 25 | $1.1B | $90.4M | ||
| Q1 25 | $1.0B | $52.7M | ||
| Q4 24 | $1.3B | $17.7M | ||
| Q3 24 | $1.3B | $-5.1M | ||
| Q2 24 | $1.2B | $-52.6M | ||
| Q1 24 | $1.2B | $-86.4M |
总资产LIVNRPD
| Q4 25 | $2.6B | $1.7B | ||
| Q3 25 | $2.6B | $1.7B | ||
| Q2 25 | $2.5B | $1.6B | ||
| Q1 25 | $2.6B | $1.6B | ||
| Q4 24 | $2.5B | $1.7B | ||
| Q3 24 | $2.5B | $1.6B | ||
| Q2 24 | $2.5B | $1.5B | ||
| Q1 24 | $2.5B | $1.5B |
负债/权益比LIVNRPD
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $82.4M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $50.2M | $36.4M |
| 自由现金流率自由现金流/营收 | 13.9% | 16.8% |
| 资本支出强度资本支出/营收 | 8.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.67× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $173.3M | $146.2M |
8季度趋势，按日历期对齐
经营现金流LIVNRPD
| Q4 25 | $82.4M | $37.6M | ||
| Q3 25 | $85.1M | $39.0M | ||
| Q2 25 | $62.9M | $47.5M | ||
| Q1 25 | $24.0M | $29.8M | ||
| Q4 24 | $78.7M | $63.8M | ||
| Q3 24 | $51.0M | $44.0M | ||
| Q2 24 | $43.4M | $32.9M | ||
| Q1 24 | $10.0M | $31.1M |
自由现金流LIVNRPD
| Q4 25 | $50.2M | $36.4M | ||
| Q3 25 | $62.2M | $34.8M | ||
| Q2 25 | $47.8M | $46.6M | ||
| Q1 25 | $13.2M | $28.4M | ||
| Q4 24 | $68.3M | $62.6M | ||
| Q3 24 | $32.8M | $42.6M | ||
| Q2 24 | $31.2M | $32.6M | ||
| Q1 24 | $3.6M | $30.4M |
自由现金流率LIVNRPD
| Q4 25 | 13.9% | 16.8% | ||
| Q3 25 | 17.4% | 16.0% | ||
| Q2 25 | 13.6% | 21.8% | ||
| Q1 25 | 4.2% | 13.5% | ||
| Q4 24 | 21.2% | 28.9% | ||
| Q3 24 | 10.3% | 19.9% | ||
| Q2 24 | 9.8% | 15.7% | ||
| Q1 24 | 1.2% | 14.8% |
资本支出强度LIVNRPD
| Q4 25 | 8.9% | 0.5% | ||
| Q3 25 | 6.4% | 1.9% | ||
| Q2 25 | 4.3% | 0.4% | ||
| Q1 25 | 3.4% | 0.6% | ||
| Q4 24 | 3.2% | 0.5% | ||
| Q3 24 | 5.7% | 0.6% | ||
| Q2 24 | 3.8% | 0.1% | ||
| Q1 24 | 2.2% | 0.3% |
现金转化率LIVNRPD
| Q4 25 | 2.67× | 12.01× | ||
| Q3 25 | 3.18× | 3.97× | ||
| Q2 25 | 2.32× | 5.70× | ||
| Q1 25 | — | 14.14× | ||
| Q4 24 | 1.41× | 29.36× | ||
| Q3 24 | 1.55× | 2.85× | ||
| Q2 24 | 2.65× | 5.03× | ||
| Q1 24 | — | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
